Day: June 14, 2025

77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 Data further support barzolvolimab clinical benefit to patients with CSUHAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1. The data were presented today by Dr. Martin Metz,...

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from the 180mg cohort of...

GREENWICH, Conn., June 13, 2025 (GLOBE NEWSWIRE) — Aetherium Acquisition (the “SPAC” or the “Company”), a publicly-traded special purpose acquisition company, today announced that its Special Meeting (“Meeting”), previously scheduled at 8:30 a.m. Eastern Time on June 13, 2025, has been postponed to 8:30 a.m. Eastern Time on June 27, 2025, and the redemption right deadline has been postponed to 5:00 p.m. Eastern Time on June 25, 2025. The record date for the Meeting remains May 9, 2025. No changes have been made to the proposals to be voted on by shareholders at the Meeting. Shareholders of the Company who have previously submitted their proxy and who do not want to change their vote do not need to take any action. On May 23, 2025, the Company filed a definitive proxy statement with the Securities and Exchange Commission (the “SEC”)...